Direct Genetics Referral Pathway for High-Grade Serous Ovarian Cancer Patients: The “Opt-Out” Process

Journal of Oncology - United States
doi 10.1155/2019/6029097
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Hindawi Limited

Related search

New in High Grade Serous Ovarian Cancer Treatment

Effective Pharmacotherapy
2019English

Predictors of Long-Term Survival Among High-Grade Serous Ovarian Cancer Patients

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2019English

PARP Inhibitors in Platinum-Sensitive High-Grade Serous Ovarian Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

Low-Stage High-Grade Serous Ovarian Carcinomas

International Journal of Gynecological Pathology
GynecologyForensic MedicinePathologyObstetrics
2016English

The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma

2019English

Retinoblastoma Pathway Deregulatory Mechanisms Determine Clinical Outcome in High-Grade Serous Ovarian Carcinoma

Modern Pathology
Forensic MedicinePathology
2013English

Molecular Abnormalities in Ovarian Cancer Subtypes Other Than High-Grade Serous Carcinoma

Journal of Oncology
Oncology
2010English

Proteome Profiling of Low Grade Serous Ovarian Cancer

Journal of Ovarian Research
GynecologyOncologyObstetrics
2019English

Integrated Analysis to Identify Molecular Biomarkers of High-Grade Serous Ovarian Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy